NASDAQ:QLGN

Qualigen Therapeutics (QLGN) Stock Price, News & Analysis

Qualigen Therapeutics logo
$0.41 0.00 (-0.63%)
As of 11/19/2026

About Qualigen Therapeutics Stock (NASDAQ:QLGN)

Advanced

Key Stats

Today's Range
$0.40
▼
$0.48
50-Day Range
$0.41
▼
$1.80
52-Week Range
$1.61
▼
$8.81
Volume
165,871 shs
Average Volume
1.52 million shs
Market Capitalization
$691.56 thousand
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Qualigen Therapeutics is a biotechnology company focused on developing investigational therapies for cancer. Its research has included QN-302, a small-molecule drug candidate, and QN-247, an aptamer-based therapeutic program. These candidates are in development and are not approved treatments.

The company historically developed diagnostic products, including its FASTPack immunoassay systems, which were designed for use in clinical laboratories and physician offices. The systems supported tests for conditions and biomarkers including prostate-specific antigen, thyroid function and testosterone levels.

Qualigen has shifted its focus from diagnostics toward oncology drug development. The company has been based in Carlsbad, California.

AI Generated. May Contain Errors.

Receive QLGN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Qualigen Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

QLGN Stock News Headlines

Drop these 5 stocks before the market opens tomorrow!
The Wall Street Journal called it the "$64 trillion question": is a stock market crash on the way? Weiss Ratings' latest research says 2026 could be very rough for some well-known stocks. A major shift now taking shape in the market could hit some of America's most-loved names hard. Weiss analysts have pinpointed five stocks they believe investors should steer clear of while it plays out.tc pixel
Qualigen Therapeutics to rebrand as AIxCrypto
See More Headlines

QLGN Stock Analysis - Frequently Asked Questions

Qualigen Therapeutics' stock was trading at $2.34 at the beginning of 2026. Since then, QLGN shares have decreased by 82.6% and is now trading at $0.4080.

Qualigen Therapeutics, Inc. (NASDAQ:QLGN) released its earnings results on Friday, November, 14th. The company reported ($4.68) earnings per share (EPS) for the quarter.

Qualigen Therapeutics's stock reverse split before market open on Tuesday, November 5th 2024.The 1-50 reverse split was announced on Friday, November 1st 2024. The number of shares owned by shareholders was adjusted after the market closes on Monday, November 4th 2024. An investor that had 100 shares of stock prior to the reverse split would have 2 shares after the split.

Qualigen Therapeutics (QLGN) raised $44 million in an initial public offering (IPO) on Friday, June 19th 2015. The company issued 4,000,000 shares at $10.00-$12.00 per share.

Shares of QLGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Qualigen Therapeutics investors own include NIO (NIO), AMC Entertainment (AMC), Vaxart (VXRT), FuelCell Energy (FCEL), Ideanomics (IDEX), Ocugen (OCGN) and Seanergy Maritime (SHIP).

Company Calendar

Today
11/20/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Software
Sub-Industry
Application Software
Current Symbol
NASDAQ:QLGN
CIK
1460702
Fax
N/A
Employees
50
Year Founded
1996

Profitability

EPS (Trailing Twelve Months)
($7.50)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$6.26 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
-202.16%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
0.71
Quick Ratio
0.71

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
($4.12) per share
Price / Book
-0.10

Miscellaneous

Outstanding Shares
1,695,000
Free Float
1,664,000
Market Cap
$691.56 thousand
Optionable
Not Optionable
Beta
0.24

Social Links

7 Blue-Chip Stocks to Add To Your Forever Portfolio Cover

A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.

This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.

Get This Free Report

This page (NASDAQ:QLGN) was last updated on 11/19/2026 by MarketBeat.com Staff.
From Our Partners